Comparison of panitumumab plus irinotecan and cetuximab plus irinotecan for KRAS wild-type metastatic colorectal cancer
T Yamaguchi, S Iwasa, K Nagashima… - Anticancer …, 2016 - ar.iiarjournals.org
Background/Aim: Panitumumab and cetuximab are known to be effective treatments for
KRAS wild-type metastatic colorectal cancer (mCRC). However, it remains unclear which of …
KRAS wild-type metastatic colorectal cancer (mCRC). However, it remains unclear which of …
Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal …
Background: The survival benefit for single-agent anti–epidermal growth factor receptor
(EGFR) therapy compared with combination therapy with irinotecan in KRAS wildtype (wt) …
(EGFR) therapy compared with combination therapy with irinotecan in KRAS wildtype (wt) …
Panitumumab after Progression on Cetuximab in KRAS Wild-type Metastatic Colorectal Cancer Patients: a Single Institution Experience
A Marino, C Caliolo, F Sponziello, A Nacci… - Tumori …, 2015 - journals.sagepub.com
Aims and background Few data describe the activity of panitumumab after cetuximab-
irinotecan-based regimen failure in patients with KRAS wild-type metastatic colorectal …
irinotecan-based regimen failure in patients with KRAS wild-type metastatic colorectal …
[HTML][HTML] Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer …
D Sakai, H Taniguchi, N Sugimoto, T Tamura… - European Journal of …, 2020 - Elsevier
Background Cetuximab has been shown to be clinically active when given in combination
with irinotecan in patients with irinotecan-refractory metastatic colorectal cancer (mCRC) …
with irinotecan in patients with irinotecan-refractory metastatic colorectal cancer (mCRC) …
[HTML][HTML] Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR …
Background The purpose of this study was to evaluate the combination of panitumumab and
irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to standard …
irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to standard …
Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in KRAS Wild-Type Metastatic Colorectal Cancer
A Townsend, N Tebbutt, C Karapetis, P Cooper… - Clinical Cancer …, 2018 - AACR
Purpose: Inhibition of mTOR in addition to EGFR may overcome resistance to EGFR
inhibitors in metastatic colorectal cancer (mCRC). This phase Ib/II study evaluated the safety …
inhibitors in metastatic colorectal cancer (mCRC). This phase Ib/II study evaluated the safety …
First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer
CH Köhne, R Hofheinz, L Mineur, H Letocha… - Journal of cancer …, 2012 - Springer
Purpose Panitumumab monotherapy is approved for KRAS wild-type (WT) metastatic
colorectal cancer (mCRC) progressing after standard chemotherapy. This study evaluated …
colorectal cancer (mCRC) progressing after standard chemotherapy. This study evaluated …
Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line …
A Tsuji, M Nakamura, T Watanabe, D Manaka… - Targeted Oncology, 2021 - Springer
Background Regorafenib and trifluridine/tipiracil are standard third-line chemotherapies for
colorectal cancer patients, but their efficacy is limited. Anti-epidermal growth factor receptor …
colorectal cancer patients, but their efficacy is limited. Anti-epidermal growth factor receptor …
A prospective, multicenter phase II study of the efficacy and feasibility of 15-minute panitumumab infusion plus irinotecan for oxaliplatin-and irinotecan-refractory …
K Akiyoshi, T Hamaguchi, K Yoshimura… - Clinical Colorectal …, 2018 - Elsevier
Background In some recently updated clinical guidelines, the fully humanized monoclonal
antibody panitumumab, combined with irinotecan, has been recommended as an optional …
antibody panitumumab, combined with irinotecan, has been recommended as an optional …
Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy
F Pietrantonio, F Perrone, P Biondani… - Cancer Biology & …, 2013 - Taylor & Francis
Background Few data are available outlining outcomes of panitumumab in advanced
colorectal cancer patients benefiting from prior cetuximab-based regimens. Patients and …
colorectal cancer patients benefiting from prior cetuximab-based regimens. Patients and …